anonymous
Guest
anonymous
Guest
Nearly a year after laying out its transformation strategy, with focus on demerging underperforming business units, Novartis (NYSE: NVA) Tuesday said it completed the spin-off of its eye care devices business Alcon. Post-spinoff, the management expects to achieve a financial position that is at par with the other leading pharmaceutical firms.